Response and Resistance to RAS Inhibition in Cancer
Richard Y. Ebright(Harvard University), Andrew J. Aguirre(Broad Institute), Julien Dilly(Massachusetts Institute of Technology), Alice T. Shaw(Dana-Farber Cancer Institute)
Cited by 36
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
<i>EGFR</i> Mutations and <i>ALK</i> Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non–Small Cell Lung Cancer: A Retrospective Analysis
|Clinical Cancer Research|2016|1.2k
Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells
|Science Translational Medicine|2013|1.1k